TY - JOUR
T1 - Lessons from next generation influenza vaccines for inflammatory disease therapies
AU - Zimmerman, Daniel H.
AU - Carambula, R. E.
AU - Ciemielewski, J.
AU - Rosenthal, K. S.
PY - 2019/9
Y1 - 2019/9
N2 - Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic ‘strains’ and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.
AB - Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic ‘strains’ and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.
KW - Immunomodulation
KW - Influenza
KW - Rheumatoid arthritis
KW - T cells
KW - Vaccine therapy
UR - http://www.scopus.com/inward/record.url?scp=85068269443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068269443&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2019.105729
DO - 10.1016/j.intimp.2019.105729
M3 - Review article
C2 - 31280056
AN - SCOPUS:85068269443
VL - 74
JO - International Immunopharmacology
JF - International Immunopharmacology
SN - 1567-5769
M1 - 105729
ER -